Tarapeutics Science Inc.
6 clinical trials · Sponsor
◉ Watch Tarapeutics Science Inc.
| Record | Firm | Date |
|---|---|---|
| TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma (NCT07639879) | Tarapeutics Science Inc. | 2026-07-30 |
| TR128 in Patients With Advanced Solid Tumors (NCT05751356) | Tarapeutics Science Inc. | 2024-02-23 |
| TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors (NCT05650580) | Tarapeutics Science Inc. | 2023-04-23 |
| TR64 in Patients With Advanced Solid Tumors (NCT05649345) | Tarapeutics Science Inc. | 2023-01-12 |
| A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT05241093) | Tarapeutics Science Inc. | 2022-03-29 |
| A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT05241106) | Tarapeutics Science Inc. | 2021-09-29 |
Track Tarapeutics Science Inc. automatically
Every clearance here is in the API, with alerts when new ones post.